Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Rhea-AI Summary
Recursion (Nasdaq: RXRX) announced it will provide business updates and report its second quarter 2026 financial results on Wednesday, August 5, 2026, before U.S. financial markets open.
The company will host a public earnings call on August 5, 2026 at 8:00 AM ET / 6:00 AM MT / 1:00 PM BST, livestreamed via its X, LinkedIn, and YouTube accounts, with questions collected through an online form.
Positive
- None.
Negative
- None.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Q1 earnings date | Neutral | -3.2% | Scheduled first-quarter results and earnings call for May 6 |
| Feb 18 | FY2025 earnings date | Neutral | +2.0% | Scheduled fourth-quarter and full-year results for February 25 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-matched earnings-date announcements produced mixed reactions, with an average 24-hour move of -0.6%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host public Earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST
Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) -- Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) – Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its second quarter 2026 financial results on Wednesday, August 5, 2026, before the open of the financial markets.
Recursion will host an earnings call on Aug 5, 2026 at 8:00 AM ET / 6:00 AM MT / 1:00 PM BST. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/wusHaT8fSqSYF71W9
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at www.recursion.com, or connect on X and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those regarding the timing of the filing of quarterly earnings; the occurrence and timing of an investor call; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar terms, or the negative of these terms. These statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; risks related to our development and use of artificial intelligence and machine learning models, including the quality, sufficiency, and integrity of the data on which such models are trained and evolving laws and regulations governing artificial intelligence; our reliance on third parties, including contract research and contract manufacturing organizations, for the conduct of preclinical studies, clinical trials, and manufacturing; competition from other companies pursuing similar technologies or drug candidates; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions and speak only as of the date of this document. Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Media Contact
media@recursion.com
Investor Contact
investor@recursion.com
Ryan Kelly Recursion Pharmaceuticals media@recursion.com